Search Results
Nov 10, 2025, 08:45 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
steatohepatitis (MASH) Semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved under accelerated approval to treat adults with MASH with moderate-to-advanced liver scarring (fibrosis), but not with cirrhosis of the
More news about: NOVO NORDISK INC.
Nov 07, 2025, 16:07 ET Conheça os procedimentos que são eficazes para melhorar o rosto flácido após perda de peso induzida por medicamentos
poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010 Mar;62(3):448-62.6. Weiss RA et al. Dermatol Surg. 2016 Jun;42(6):699-709 8. Bonhert K, et al. Randomized, Controlled,
More news about: Galderma
Nov 07, 2025, 11:55 ET BSA Announces Election Results for 2026 Board of Directors and Governance Committees
Nominating Committee Karl Heckmaev, RA — Architect, City of Boston Mayor's Office of Housing Magda Maaoui, PhD — Faculty, Harvard University
More news about: Boston Society for Architecture
Nov 06, 2025, 14:30 ET Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
disease, with or without type 2 diabetes. Safety data generated in the REDEFINE 1 trial were comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo. In REDEFINE 1, adverse events were
More news about: NOVO NORDISK INC.
Nov 06, 2025, 14:30 ET Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
cardiovascular disease, with or without type 2 diabetes. Safety data generated in the REDEFINE 1 trial were comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo. In REDEFINE 1, adverse events were
More news about: NOVO NORDISK INC.
Nov 05, 2025, 17:31 ET Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight
central role in driving inflammation, tissue destruction, and clinical manifestations of rheumatoid arthritis (RA). It is considered particularly effective during the onset and flare-ups of RA, with strong potential to prevent joint damage and disease progression. The drug is currently in Phase II clinical
More news about: DelveInsight Business Research, LLP
Nov 04, 2025, 19:10 ET Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
that of the GLP-1R agonist class. Abstract Title: ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity: A Ph Ib Study Results: The observed half-life (time for ASC30 concentrations
More news about: Ascletis Pharma Inc.
Nov 04, 2025, 03:00 ET Healthcare Holding Schweiz erwirbt Anteile an QUNIQUE
Bereichen IVDR (In-Vitro-Diagnostik Verordnung), MDR (Medizinprodukteverordnung), MDSAP (Medical Device Single Audit Program), QM (Qualitätsmanagement), RA (Regulatory Affairs), Schulungen, Audits sowie Technische Dokumentation. QUNIQUE ist darüber hinaus als CH/EU-REP (Schweizer und Europäischer Bevollmächtigter)
More news about: Healthcare Holding Schweiz AG
Nov 04, 2025, 03:00 ET Healthcare Holding Schweiz Acquires a Stake in QUNIQUE
including IVDR (In Vitro Diagnostic Regulation), MDR (Medical Device Regulation), MDSAP (Medical Device Single Audit Program), QM (Quality Management), RA (Regulatory Affairs), training, audits, and technical documentation. In addition, QUNIQUE acts as CH/EU-REP (Swiss and European Authorized Representative)
More news about: Healthcare Holding Schweiz AG
Nov 04, 2025, 03:00 ET Healthcare Holding Schweiz Acquires a Stake in QUNIQUE
including IVDR (In Vitro Diagnostic Regulation), MDR (Medical Device Regulation), MDSAP (Medical Device Single Audit Program), QM (Quality Management), RA (Regulatory Affairs), training, audits, and technical documentation. In addition, QUNIQUE acts as CH/EU-REP (Swiss and European Authorized Representative)
More news about: Healthcare Holding Schweiz AG
Nov 03, 2025, 19:06 ET Energy Fuels Announces Q3-2025 Results
the same time, parallel with its Ra-226 process development activities, the Company has applied for a license to concentrate R&D quantities of Ra-228 at the Mill and is currently performing engineering on its process development and R&D pilot facility for Ra-228 production.
More news about: Energy Fuels Inc.
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
SELECT-SWITCH study evaluating the efficacy and safety of Rinvoq compared to Humira (adalimumab) in adult patients with moderate to severe rheumatoid arthritis (RA), who had an inadequate response or intolerance to a single TNF inhibitor other than Humira. In the study, Rinvoq demonstrated superiority versus Humira
More news about: AbbVie
Oct 30, 2025, 04:00 ET AbolerIS Pharma Appoints Seasoned Life-Sciences Executive Philippe Alen as Chief Business Officer
designed to demonstrate broad efficacy in multiple autoimmune and inflammatory disorders with large unmet medical needs including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and organ transplantation. At AbolerIS, we envision a future where patients can enjoy long-term
More news about: AbolerIS Pharma
Oct 29, 2025, 08:11 ET AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
More news about: AbbVie
Oct 29, 2025, 05:00 ET De juego de lucha profesional a aventura de bolsillo: Brook abre tiendas Amazon en toda Europa
Brook ofrece una amplia gama de productos para todo tipo de jugadores. La serie Pocket está diseñada para juegos móviles basados en RA como Pokémon GO, con funciones como captura automática, recolección automática y simulación de GPS:
More news about: Brook Gaming (Zeroplus Technology Co., Ltd.)
Oct 28, 2025, 15:05 ET Cisco Delivers AI Innovations across Neocloud, Enterprise and Telecom with NVIDIA
our biggest scaling challenge. Cisco's Nexus N9100 series platform based on NVIDIA Spectrum-X Ethernet switch silicon directly addresses this with NCP RA compliance - giving us the performance we need with the openness we require. The unified Nexus operating model is particularly compelling as it maintains
More news about: Cisco Systems, Inc.
Oct 28, 2025, 08:00 ET RheumaGen Presents HLA Gene-Editing Preclinical Data for Nearly Universal Autoimmune Disease Target at ACR Convergence 2025 Oral Session
at position 82 of an HLA molecule, or anchor-position editing, substantially blocks three of the most critical self-peptides in rheumatoid arthritis (RA) from being presented to T cells. This data was featured in an oral presentation by Vibha Jha, Ph.D., from the Center for Clinical Immunology at the
More news about: RheumaGen, Inc.
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
dysfunction-associated steatohepatitis ( MASH)Semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved under accelerated approval to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the
More news about: NOVO NORDISK INC.
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
dysfunction-associated steatohepatitis ( MASH)Semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved under accelerated approval to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the
More news about: NOVO NORDISK INC.
Oct 27, 2025, 17:02 ET Autocuidado masculino: homens recorrem a procedimentos estéticos para realçar a beleza e cuidar da pele
https://www.isaps.org/media/razfvmsk/isaps-global-survey-2024.pdf . Acessado em 17 de setembro de 2025. 2. Weiss RA et al. Dermatol Surg. 2016 Jun;42(6):699-709 3. Di Gregorio C et al. Clin Cosmet Investig
More news about: Galderma
Oct 27, 2025, 10:59 ET PORT AUTHORITY AND NEW TERMINAL ONE ANNOUNCE ROSTER OF INTERNATIONALLY RECOGNIZED ARTISTS TO CREATE MONUMENTAL COMMISSIONS AT JOHN F. KENNEDY INTERNATIONAL AIRPORT
transportation hub and cultural landmark. Yinka Shonibare CBE RA has created Kites for Queens, a monumental installation that will include nine hand-painted Dutch wax batik kites that celebrate the multicultural
More news about: The New Terminal One at JFK
Oct 27, 2025, 08:02 ET TAG1 and NRG PALLAS Expand Partnership to Enable European Access to TAG1 Lead-212 Generator and Expand Radium-224 Supply
infrastructure needed to support radiopharmaceutical advancement worldwide. It follows TAG1 and NRG PALLAS's 2024 partnership focused on establishing long-term Ra-224 and Pb-212 production for use in cancer therapeutics. About TAG1 Inc.TAG1 Inc. is a leading
More news about: TAG1, Inc.
Oct 27, 2025, 06:00 ET Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025
2025, 7:30 p.m.-8:30 p.m., EST Abstract Title: ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity: A Ph Ib Study Presentation Time: November 4, 2025, 7:30 p.m.-8:30 p.m.,
More news about: Ascletis Pharma Inc.
Oct 27, 2025, 06:00 ET Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders
participation from additional new investors including a large global sovereign wealth fund, and Avoro Capital Advisors, alongside existing investors RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital.
More news about: Hemab Therapeutics
Oct 26, 2025, 14:08 ET l 14º Festival Internacional de Cine de Teléfonos Inteligentes MINA es copresentado por SmallRig:57 películas móviles de 21 países debutan en Melbourne
comunitaria y producciones cinematográficas experimentales. También destaca medios emergentes como la cinematografía con drones, la realidad aumentada (RA), la realidad virtual (RV) móvil y la inteligencia artificial (IA) móvil. Para obtener m
More news about: SmallRig